About: Paul Lorigan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Paul Lorigan Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) ikertzailea (eu) researcher (en) 연구원 (ko) ricercatore (it) গবেষক (bn) 研究者 (ja) investigador (es) araştırmacı (tr) chercheur (fr) wetenschapper (nl) дослідник (uk) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtues (sq) researcher (en-ca) researcher (en-gb) researcher (en-us) investigador (ca) investigador (gl) investigador (ast) investigador (pt)
rdfs:label	Paul Lorigan (en) Paul Lorigan (es) Paul Lorigan (it) Paul Lorigan (nl) Paul Lorigan (sl)
skos:prefLabel	Paul Lorigan (en) Paul Lorigan (es) Paul Lorigan (it) Paul Lorigan (nl) Paul Lorigan (sl)
name	Paul Lorigan (en) Paul Lorigan (es) Paul Lorigan (it) Paul Lorigan (nl) Paul Lorigan (sl)
Scopus author ID	wds:Q32649737-7CEC3A07-9DCF-431B-964F-52477AAE22CB
Scopus author ID	6604053967
given name	wds:Q32649737-f4de707b-4a7d-db5e-2668-04b0973117f4
given name	Paul
instance of	wds:Q32649737-1C071E91-2571-4CCC-9B47-7D2D718FA283
instance of	Homo sapiens
occupation	wds:Q32649737-869aab75-42be-0450-9b48-e29fe6277269
employer	wds:Q32649737-26F4C595-14E6-4738-A551-ED37A029D9A2 wds:Q32649737-2C85196B-AF17-41F9-9C5D-D36A29471572 wds:Q32649737-4C37F7E7-5C39-4ED8-A3AE-AE5B7437ED02 wds:Q32649737-729533D0-389F-4911-9F59-D09E3F90CF56 wds:Q32649737-81EAE280-4F57-4EAF-A835-4D0BFD4084EE wds:Q32649737-CED41388-53B1-4BBE-A3D5-49407B081A00
sex or gender	wds:Q32649737-B3FAA7A1-D681-42E2-B718-FD510B345080
educated at	wds:Q32649737-7D200385-4DDD-497D-8A10-5055A6F58B0E
family name	wds:Q32649737-BB5D25A9-0478-4459-B806-08C77B926B2F
official website	wds:Q32649737-2DC748C7-D680-438B-A4A8-F16040FC2309 wds:Q32649737-65b787e0-4658-2c71-94ee-7ff6819548e9
occupation	researcher
employer	Wythenshawe Hospital University of Manchester Royal Lancaster Infirmary Respond! The Christie NHS Foundation Trust
sex or gender	male
educated at	University College Dublin
family name	Lorigan
official website	https://pureprojects.ppad.man.ac.uk/portal/en/researchers/paul-lorigan(d695629b-4405-4455-9a26-aaf14c721b6c).html https://www.research.manchester.ac.uk/portal/paul.c.lorigan.html
Springer Nature person ID	wds:Q32649737-F5B00723-CC28-4118-BF7F-E29D4A8F8E2B
ORCID iD	wds:Q32649737-0d66e0ce-4984-acf0-caea-3f282fda5b00
Dimensions author ID	wds:Q32649737-8E51227C-56E5-433E-BA7B-4492F9F8E866
ORCID iD	https://orcid.org/0000-0002-8875-2164
Springer Nature person ID	01223762727.50
ORCID iD	0000-0002-8875-2164
Dimensions author ID	01223762727.50
ResearcherID	wds:Q32649737-BAAA935C-249D-4DB6-9691-A6343C33C437
Publons author ID	wds:Q32649737-d5922fca-6576-4236-8d48-bd68416ff50c
ResearcherID	J-6898-2015
Publons author ID	2376045
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q32649737
is author of	TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Improved overall survival in melanoma with combined dabrafenib and trametinib A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud Improved survival with vemurafenib in melanoma with BRAF V600E mutation Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism? Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software